-
1.发明公开$i(EX VIVO) TREATMENT OF ALLOGENEIC AND XENOGENEIC T-CELLS WITH gp39 ANTAGONISTS 有权EX VIVO治疗gp39拮抗异体异种细胞和T细胞的
公开(公告)号：EP1100515A1
公开(公告)日：2001-05-23
申请号：EP99944997.8
申请日：1999-07-29
IPC分类号： A61K35/00 , A61K35/12 , A61K35/14 , A61K35/26 , A61K35/28 , A61K39/395 , C12N5/02 , C12N5/06
CPC分类号： A61K39/001 , A61K2035/122 , A61K2035/124 , A61K2039/5158 , C07K16/2875 , C12N5/0636 , C12N2501/52
摘要： Methods for inducing T-cell non-responsiveness to donor T-cells comprised in transplantation tissues are provided. The methods involve ex vivo treatment of donor T-cells with gp39 antagonists.
-
2.发明授权EX VIVO TREATMENT OF ALLOGENEIC AND XENOGENEIC T-CELLS WITH gp39 ANTAGONISTS 有权EX VIVO治疗gp39拮抗异体异种细胞和T细胞的
公开(公告)号：EP1100515B1
公开(公告)日：2005-11-16
申请号：EP99944997.8
申请日：1999-07-29
IPC分类号： A61K35/14 , A61K39/395 , C12N5/06 , A61P37/06
CPC分类号： A61K39/001 , A61K2035/122 , A61K2035/124 , A61K2039/5158 , C07K16/2875 , C12N5/0636 , C12N2501/52
摘要： Methods for inducing T-cell non-responsiveness to donor T-cells comprised in transplantation tissues are provided. The methods involve ex vivo treatment of donor T-cells with gp39 antagonists.
-
公开(公告)号：EP4041757A1
公开(公告)日：2022-08-17
申请号：EP20870067.4
申请日：2020-09-25
-
公开(公告)号：EP4031565A1
公开(公告)日：2022-07-27
申请号：EP20864423.7
申请日：2020-09-15
-
公开(公告)号：EP2197909A2
公开(公告)日：2010-06-23
申请号：EP08828457.5
申请日：2008-08-25
发明人： VALLERA, Daniel, A.
IPC分类号： C07K14/705 , C07K19/00 , C12N15/62 , A61K38/17 , A61P35/00
CPC分类号： A61K38/1709 , A61K47/64 , A61K47/642 , A61K51/088 , C07K14/485 , C07K14/5406 , C07K14/5437 , C07K2319/04 , C07K2319/55 , C07K2319/74
摘要： The present disclosure features, inter alia, receptor-targeting reagents (e.g., immunotoxic receptor-targeting reagents), which are useful in, e.g., methods of binding a receptor-targeting reagent to a cell and methods for treating a variety of disorders such as, but not limited to, cancers and inflammatory disorders. Also featured are methods, compositions, and kits useful for selecting an appropriate treatment modality for a subject (e.g., a subject with a cancer or inflammatory disorder) and/or treating a variety of disorders such as cell proliferative disorders.
-
公开(公告)号：EP3867278A1
公开(公告)日：2021-08-25
申请号：EP19873982.3
申请日：2019-10-17
-
7.发明公开
公开(公告)号：EP2576620A1
公开(公告)日：2013-04-10
申请号：EP10791033.3
申请日：2010-12-10
IPC分类号： C07K16/28 , A61K39/395 , C07K16/30 , C07K19/00 , G01N33/53
CPC分类号： C07K16/22 , A61K2039/505 , A61K2039/507 , C07K16/2863 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/303 , C07K16/3046 , C07K2317/622 , C07K2317/73 , C07K2319/21 , C07K2319/42 , C07K2319/55 , G01N2333/70596
摘要： Disclosed herein are a monoclonal antibody that specifically binds to human CD 133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.
-
公开(公告)号：EP0784482A2
公开(公告)日：1997-07-23
申请号：EP95922279.0
申请日：1995-06-07
CPC分类号： C07K14/70521 , A61K38/00 , C07K16/247 , C07K16/2827 , C07K16/2845 , C07K16/2866 , C07K2319/00
摘要： Methods for inhibiting antigen-specific T cell responses by use of an agent which inhibits a costimulatory signal in T cells are disclosed. Preferably, both a first agent which inhibits a costimulatory signal in the T cell (e.g., a CTLA4Ig fusion protein) and a second agent which inhibits another T cell function, such as adhesion of the T cell to a cell presenting antigen to the T cell, are used to inhibit antigen-specific T cell responses. For example, to inhibit adhesion of a T cell to a cell presenting antigen, an anti-LFA-1 antibody can be used in conjunction with a CTLA4Ig fusion protein. Alternatively, another agent which inhibits a costimulatory signal in T cells, such as an anti-B7-1 antibody or an anti-B7-2 antibody can be used with a second agent which inhibits a proliferative signal in the T cell e.g., an anti-IL-2 receptor antibody. The methods of the invention are particularly useful for inhibiting graft versus host disease and for inhibiting rejection of a transplanted tissue or organ.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.045 秒)
